Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 2 3Phase 4 2Phase 1 2Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 58Rituximab 54fludarabine 33fludarabine phosphate 32venetoclax 24Filgrastim 22Etoposide 18Bendamustine Hydrochloride 18Gemcitabine 17Peripheral Blood Stem Cell Transplantation 15Bortezomib 15Melphalan 14obinutuzumab 13Lenalidomide 12Dexamethasone 12Cytarabine 12Vincristine 11Vorinostat 10Tacrolimus 10Azacitidine 10pembrolizumab 9Prednisone 9Mycophenolic Acid 9Doxorubicin 9ibrutinib 8copanlisib 8Whole-Body Irradiation 8Radiotherapy 8Paclitaxel 8Interleukin-2 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Non-Hodgkin × pirtobrutinib × Clear all
NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Eli Lilly and Company

Phase 1 Active not recruiting
316 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05990465 2026-02-23

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Medical College of Wisconsin

Phase 1 Recruiting
12 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡